Índice Bovespa

US Dollar vs BRL

Cadastre-se para interagir em nossos fóruns de ativos e discutir com investidores ideias semelhantes.

Cadastre-se

MDGL Madrigal Pharmaceuticals Inc

215,93

-2,45 (-1,12%)

Última atualização: 11:24:25

Atrasado em 15 minutos

Madrigal Pharmaceuticals Q4 net loss widens Y/Y

To read the full story on Seeking Alpha, click here.

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Click aqui para mais gráficos Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024

Click aqui para mais gráficos Madrigal Pharmaceuticals.

Notícias Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Terça, 23 de Abril de 2024 (1 dia atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Terça, 16 de Abril de 2024 (1 semana atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Terça, 9 de Abril de 2024 (2 semanas atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Quarta, 3 de Abril de 2024 (3 semanas atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Terça, 19 de Março de 2024 (1 mês atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces Proposed Public Offering
Segunda, 18 de Março de 2024 (1 mês atrás) • GlobeNewswire Inc.

Adobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More News
Sexta, 15 de Março de 2024 (1 mês atrás) • IH Market News

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Quinta, 14 de Março de 2024 (1 mês atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Quarta, 6 de Março de 2024 (2 meses atrás) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Terça, 5 de Março de 2024 (2 meses atrás) • GlobeNewswire Inc.

Form 8-K - Current report
Quarta, 28 de Fevereiro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quarta, 28 de Fevereiro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Madrigal Pharmaceuticals Inc

Índice Bovespa

$Logo da Infracommerce Caxaas ON (IFCM3).$

Infracommerce Caxaas ON

PÃO DE AÇUCAR ON

Pet Center Comercio E Pa... ON

MAGAZINE LUIZA ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições